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genes that have not been shown to be mutated in TCGA 
subset of Her-2 overexpressing breast cancer: CTNNB1, 
HRAS, KRAS, NF2 and SMARCB1.
Conclusion Mutational burden in heavily treated trastu-
zumab-resistant Her2-positive metastatic breast cancer is 
highly variable and not directly correlated with outcome. 
Activation of the MAPK/ERK pathway through muta-
tions in EGFR, BRAF or KIT may mediate resistance to 
trastuzumab.
Keywords Her2 · Trastuzumab · Everolimus · Metastatic 
breast cancer · Phosphoinositol 3-kinase · mTOR
Introduction
Breast cancer (BC) is the most prevalent non-skin cancer in 
women, accounting for ~40,000 deaths per year in the USA 
(Siegel et  al. 2012). About one quarter of patients with 
BC overexpress Her2, which is associated with decreased 
overall survival (OS) (Slamon et  al. 1987). The majority 
of patients with Her2-positive disease receive trastuzumab 
as part of their treatment. This monoclonal antibody tar-
gets the extracellular domain of the HER2 receptor and has 
significantly increased OS for this subset of patients (Sla-
mon et al. 2001). Unfortunately, not all patients respond to 
trastuzumab-based therapies and some develop secondary 
resistance after disease remission. The precise mechanisms 
behind trastuzumab resistance are not fully understood, 
but some have implicated activation of the phosphoinosi-
tol 3-kinase (PI3K) pathway (Berns et al. 2007). Activation 
of PI3K pathway through PIK3CA mutations or PTEN loss 
would lead to cell growth through mTOR-mediated sign-
aling, effectively rendering proliferating signals from epi-
dermal growth factor receptors, such as HER2, redundant 
Abstract 
Purpose Resistance to trastuzumab therapy is linked to 
phosphoinositol 3-kinase (PI3K) pathway activation. One 
key downstream effector and regulator of this pathway is 
the mechanistic target of rapamycin (mTOR). In 2011, a 
phase I/II study evaluated the combination of trastuzumab 
and everolimus (a mTOR inhibitor) for treatment of Her2-
positive metastatic breast cancer (MBC) for patients who 
had progressed on trastuzumab-based therapy.
Methods We retrospectively analyzed GeneChip microar-
ray data from 22 of 47 patients included in the study.
Results Using an unbiased approach, we found that muta-
tions in BRAF, EGFR and KIT are significantly more com-
mon in this heavily treated population when compared with 
the cohort of invasive breast carcinoma patients in The 
Cancer Genome Atlas (TCGA). Furthermore, 10 out of 22 
patients had PIK3CA mutations (45.4%) but PI3KCA sta-
tus was not predictive of PFS in our cohort. Finally, the use 
of  OncoScantm has allowed us to detected mutations in five 
 * Gerburg M. Wulf 
 gwulf@bidmc.harvard.edu
1 Department of Medicine, Beth Israel Deaconess Medical 
Center, Boston, MA, USA
2 Harvard Medical School, Boston, MA, USA
3 Present Address: University of Connecticut, Storrs, CT, USA
4 Affymetrix, San Francisco, CA, USA
5 Present Address: Vitruvian Networks, San Francisco, CA, 
USA
6 MD Anderson, Houston, TX, USA
7 Present Address: Perlmutter Cancer Center, NYU Langone 
Medical Center, New York, NY, USA
8 Weill Cornell Medical College, New York, NY, USA
 J Cancer Res Clin Oncol
1 3
(Nagata et  al. 2004). Multiple phase I/II trials were done 
to evaluate the safety and efficacy of using everolimus—a 
mTOR inhibitor—in patients who had progressed on tras-
tuzumab-based therapies (André et al. 2014, 2016; Hurvitz 
et al. 2015; Morrow et al. 2011a). In the present study, we 
have retrospectively analyzed the genomic characteristics 
of patients included in one of such studies, whose results 
were published in the Journal of Clinical Oncology in 2011 
(Morrow et al. 2011a).
Results
Mutations in trastuzumab-resistant Her2-positive 
metastatic breast cancer
Archival tumor, pre-dating the exposure to trastuzumab 
and everolimus, was used for DNA extraction. After qual-
ity control, 22 samples were submitted to DNA microarray 
panel (Affymetrix  Oncoscan™), a genomic screening tool 
based on molecular inversion probe (MIP) technology for 
identifying copy number alterations, loss of heterozygosity 
(LOH), and somatic mutations (Wang et  al. 2005, 2007, 
2009). We identified 42 different mutations in 26 genes 
(Table 1). The most frequently mutated gene was PIK3CA 
(ten patients—45.4%) followed by BRAF, EGFR and KIT 
(two patients each—13.6%) (Table 2).
The Oncoscan™ method identified fewer mutations 
in TP53 than would be expected (Nik-Zainal et  al. 2016; 
Ciriello et al. 2015). This is likely due to the fact that the 
chip-based assay did not capture the range of different 
TP53 mutations seen in breast cancer. For example, in the 
BC TCGA cohort there are 346 patients with 201 differ-
ent TP53 mutations (Ciriello et al. 2015). Our probe panel 
included 34 different probes targeting TP53 mutations 
(Table  3). Only 21 of those are represented in the group 
of 201 mutations described in TCGA in BC (Ciriello et al. 
2015). Hence, it is not surprising that we only found a 
single mutation (a mutation on codon 220 that leads to a 
change from tyrosine to cysteine), already described in BC 
and present in only six of the 346 patients with mutated 
TP53 in TCGA BC cohort. Because of this methodo-
logical constraint, we excluded TP53 from analysis of our 
cohort. Of note, TP53 was differentially mutated in Her2-
positive (n = 120) versus Her2-negative (n = 985) tumors 
in BC TCGA with 46.7% of Her2-positive tumors carry-
ing a TP53 mutation versus 29.4% of Her2-negative tumors 
(Table 4a, p = 0.0002).
The total number of mutations was variable (Table  5) 
between patients, and  OncoScan™ did not detect any muta-
tions in 6/22 patients. Mutational burden did not correlate 
with progression-free survival (PFS) (R square = 0.0297, 
P = 0.4429) (Fig. 1a).
Aside from TP53, which cannot be compared because 
of the methodological limitations mentioned above, the 
mutational pattern found in our patient population (n = 22), 
who had trastuzumab-resistant MBC, was not significantly 
different (defined as P < 0.0020, see Methods) from Her2-
positive samples in TCGA (Table 5b). Of note, five genes 
mutated in our cohort—CTNNB1, HRAS, KRAS, NF2, 
Table 1  List of mutations found in tumor DNA using Affymetrix 
 OncoScan™ GeneChip
Gene: mutation # of patients
ABL1: MUT = Y253H 1
APC: MUT = Q1294X 1
APC: MUT = R1114X 1
ATM: MUT = Q2442P 1
BRAF: MUT = G469E 1
BRAF: MUT = I326T 2
BRCA1: MUT = G778C 2
BRCA1: MUT = W372X 1
CSF1R: MUT = Y969H 1
CTNNB1: MUT = D32N 1
CTNNB1: MUT = S45P 1
EGFR: MUT = R108K 2
EGFR: MUT = R677H 1
ERBB2: MUT = L755S 1
FBXW7: MUT = R393X 1
HRAS: MUT = Q61P 1
KIT: MUT = E839K 2
KIT: MUT = V825A 1
KRAS: MUT = Q61K 2
MAP2K4: MUT = S184L 1
MET: MUT = 982 complex variant 1
MET: MUT = R988C 1
MSH2: MUT = R711X 1
NF1: MUT = R304X 1
NF2: MUT = Q362X 2
NF2: MUT = R262X 1
PIK3CA: MUT = C901F 2
PIK3CA: MUT = E542K 2
PIK3CA: MUT = E545K 4
PIK3CA: MUT = H1047R 5
PIK3CA: MUT = R108H 2
PIK3CA: MUT = R38H 1
PTEN: MUT = C165 1
SMAD4: MUT = E330A 1
SMAD4: MUT = R445X 1
SMARCB1: MUT = R158X 1
SMARCB1: MUT = Y47X 1
SMO: MUT = W535L 2
WT1: MUT = F154S 1
WT1: MUT = R301X 1
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SMARCB1—had not been previously observed in Her2-
positive tumors in TCGA.
Finally, we compared our cohort with all TCGA 
breast cancer samples (n = 1105) (Table  5c). Three genes 
were found to be more commonly mutated amongst our 
patients than in TCGA: BRAF (13.6 vs 0.2%, P = 0.0001), 
EGFR (13.6 vs 0.7%, P = 0.0010) and KIT (13.6 vs 0.7%, 
P = 0.0010).
Mutations in PIK3CA did not show prognostic value 
in our cohort
In our cohort, we found six different PIK3CA mutations, 
occurring in 10/22 patients. The difference in prevalence 
in our cohort (45.4%) and TCGA (30.8%) did not reach 
statistical significance (P = 0.1631). PIK3CA is the most 
frequently mutated gene in our cohort and second only 
to TP53 in TCGA. Out of the ten patients in our cohort, 
two patients had three mutations in PIK3CA, one patient 
had two mutations and the remaining seven had one muta-
tion each (Table  5). Not surprisingly, the most common 
mutation found was the mutation H1047R, found in five 
patients. It localizes to the highly conserved kinase domain 
and results in enhanced downstream signaling (Kang et al. 
2005). E545K and E542K mutations were found in four 
and two patients respectively. Both localize to the helical 
domain and also lead to enhanced downstream signaling 
(Kang et al. 2005). In our cohort, two patients had a C901F 
mutation, one of them having two other concomitant muta-
tions in PIK3CA (E545K, R108H). The C901F mutation 
localizes to the kinase domain and results in a cysteine to 
phenylalanine change. It has been described in endometrial 
carcinoma (Garcia-Dios et al. 2013), but it is rare in BC. In 
TCGA patients with BC it was found only in one patient, 
concurrent with an E542K mutation. The two other muta-
tions in PIK3CA found in our cohort, R108H and R38H, 
were present in two and one patients, respectively. R38H 
localizes to the p85-binding domain of PI3K and R108H is 
a mutation that changes an arginine into a histidine in the 
amino acid immediately following the p85-binding domain. 
Both of these mutations have been described in endometrial 
carcinoma (Samuels et al. 2004) but are rare in BC. R38H 
is not present in BC TCGA cohort and R108H is found 
in only one patient in conjunction with the more common 
H1047R mutation.
Based on previous studies that suggested that activa-
tion of the PI3K pathway in Her2-positive tumors (through 
either PIK3CA mutations or PTEN loss) is associated with 
a worse prognosis (Andre et al. 2016), we analyzed whether 
PIK3CA mutations in our patients carried any prognos-
tic value. From the 22 patients included, 12 had wild-type 
PIK3CA and 10 had PIK3CA mutations. Median PFS on 
treatment with trastuzumab and everolimus was 126.0 and 
79.0 days, respectively, but PFS curves did not differ signif-
icantly between the two groups (P = 0.5353) (Fig. 1b). We 
also grouped patients with PIK3CA mutation and/or PTEN 
loss, both of which lead to PI3K activation, and compared 
them with patients without neither PIK3CA mutation nor 
PTEN loss. We excluded four patients from this analysis 
since PTEN status was not available. This comparison also 
yielded a non-significant result: median PFS of 152.0 and 
110.0 days, respectively (P = 0.3232) (Fig. 1c).
Influence of estrogen receptor (ER) status on mutations 
in Her2-positive BC
Finally, we examined whether there were mutations that 
were exclusively present in Her2-positive ER-positive ver-
sus Her2-positive ER-negative tumors in our cohort as the 
presence or absence of ER may have an impact on thera-
peutic decisions and efficacy (Schettini et al. 2016). In our 
patients, ABL1, ATM, CSF1R, CTNNB1, ERBB2, HRAS, 
Table 2  Prevalence of mutations in each gene represented in our 
cohort ranked according to the most mutated genes in TCGA cohort
Data presented as numbers of patients with mutated gene and per-
centage of patients affected in that cohort
TCGA: Her2− 
only (n = 985)
TCGA: 
Her2 + only 
(n = 120)
JCO 2011 (n = 22)
PIK3CA 303 (30.8%) 37 (30.8%) 10 (45.4%)
TP53 290 (29.4%) 56 (46.7%) n/a
PTEN 50 (5.1%) 4 (3.3%) 1 (4.5%)
MAP2K4 32 (3.2%) 2 (1.7%) 1 (4.5%)
NF1 29 (2.9%) 4 (3.3%) 1 (4.5%)
BRCA1 23 (2.3%) 1 (0.8%) 3 (13.6%)
ATM 22 (2.2%) 3 (2.5%) 1 (4.5%)
ERBB2 21 (2.1%) 4 (3.3%) 1 (4.5%)
APC 14 (1.4%) 2 (1.7%) 2 (9.0%)
FBXW7 14 (1.4%) 1 (0.8%) 1 (4.5%)
ABL1 7 (0.7%) 2 (1.7%) 1 (4.5%)
EGFR 7 (0.7%) 1 (0.8%) 3 (13.6%)
KIT 7 (0.7%) 1 (0.8%) 3 (13.6%)
KRAS 7 (0.7%) 0 (0.0%) 2 (9.0%)
MET 7 (0.7%) 2 (1.7%) 2 (9.0%)
MSH2 6 (0.6%) 2 (1.7%) 1 (4.5%)
SMAD4 6 (0.6%) 2 (1.7%) 2 (9.0%)
NF2 4 (0.4%) 0 (0.0%) 2 (9.0%)
SMARCB1 4 (0.4%) 0 (0.0%) 2 (9.0%)
SMO 4 (0.4%) 1 (0.8%) 2 (9.0%)
HRAS 3 (0.3%) 0 (0.0%) 1 (4.5%)
BRAF 2 (0.2%) 3 (2.5%) 3 (13.6%)
CSF1R 2 (0.2%) 2 (1.7%) 1 (4.5%)
CTNNB1 2 (0.2%) 0 (0.0%) 2 (9.0%)
WT1 2 (0.2%) 1 (0.8%) 2 (9.0%)
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MAP2K4, NF1 and PTEN mutations were found only on 
Her2-positive ER-negative BC (n = 13) while APC, FBXW7 
and MSH2 mutations were solely found on Her2-positive 
ER-positive samples (n = 9).
Discussion
Our study describes the genetic background of breast 
tumors from a highly selected population of patients with 
trastuzumab-resistant Her2-positive metastatic breast 
cancers. The advent of trastuzumab and other therapies 
that target HER2/neu has changed the clinical course for 
patients diagnosed with this subset of BC (Balduzzi et al. 
2014). Even more effective therapies using trastuzumab 
emtansine (T-DM1), an antibody–drug conjugate, are now 
available (Verma et al. 2012). Unfortunately, resistance to 
trastuzumab and other therapies that target the HER2/neu 
pathway still occurs and some patients do not benefit from 
trastuzumab-based drug regimen. That prompted phase I/
II clinical trials that evaluated the benefit of adding everoli-
mus to trastuzumab-based therapies after progression of 
disease while on trastuzumab (Morrow et al. 2011b). The 
combination of everolimus and trastuzumab led to partial 
responses (PR) in 7/47 patients (15%) and persistent stable 
disease (PSD) in 9/47 patients (19%), which amounts to a 
clinical benefit rate (CBR) of 34% (Morrow et al. 2011b).
Table 3  Tags used to screen for TP53 mutations using Affymetrix 
 OncoScan™



































Table 4  Comparison between number of patients with mutations and 
without mutations in each cohort using Fischer’s exact test
P < 0.0020 defined as significant (in bold) based on Bonferroni cor-
rection for multiple comparisons. (a) Comparison between TCGA 
Her2-negative BC (n = 985) and TCGA Her2-positive BC (n = 120); 
(b) comparison between TCGA Her2-positive BC (n = 120) and this 
study Her2-positive trastuzumab-resistant MBC cohort (n = 22); (c) 
comparison between this study Her2-positive trastuzumab-resistant 
MBC cohort (n = 22) and all TCGA BC (n = 1105)
a. TCGA Her2- vs 
TCGA Her2+
b. TCGA Her2 + vs 
JCO 2011
c. JCO 2011 versus 
TCGA
Gene P value Gene P value Gene P value
ABL1 0.3386 ABL1 0.3989 ABL1 0.1625
APC 0.6896 APC 0.1134 APC 0.0454
ATM 0.7470 ATM 0.4940 ATM 0.4018
BRAF 0.0106 BRAF 0.0477 BRAF <0.0001
BRCA1 0.5041 BRCA1 0.0118 BRCA1 0.0170
CSF1R 0.0606 CSF1R 0.3989 CSF1R 0.0642
CTNNB1 1.0000 CTNNB1 0.0231 CTNNB1 0.0027
EGFR 0.6026 EGFR 0.0118 EGFR 0.0010
ERBB2 0.3388 ERBB2 0.5747 ERBB2 0.3881
FBXW7 1.0000 FBXW7 0.2868 FBXW7 0.2837
HRAS 1.0000 HRAS 0.1549 HRAS 0.0847
KIT 0.6026 KIT 0.0118 KIT 0.0010
KRAS 1.0000 KRAS 0.0231 KRAS 0.0150
MAP2K4 0.5721 MAP2K4 0.3989 MAP2K4 0.5233
MET 0.2548 MET 0.1134 MET 0.0150
MSH2 0.2125 MSH2 0.3989 MSH2 0.1437
NF1 0.7754 NF1 0.5747 NF1 0.4896
NF2 1.0000 NF2 0.0231 NF2 0.0065
PIK3CA 1.0000 PIK3CA 0.2194 PIK3CA 0.1631
PTEN 0.5062 PTEN 0.5747 PTEN 1.0000
SMAD4 0.2125 SMAD4 0.1134 SMAD4 0.0118
SMARCB1 1.0000 SMARCB1 0.0231 SMARCB1 0.0065
SMO 0.4378 SMO 0.0626 SMO 0.0065
TP53 0.0002 TP53 n/a TP53 n/a
WT1 0.2919 WT1 0.0626 WT1 0.0027
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In BOLERO-3—a randomized, double-blind, placebo-
controlled phase 3 trial that evaluated adding everolimus in 
that same setting—addition of everolimus increased median 
PFS from 5.78 to 7.00  months (P = 0.0067), although the 
toxicity of the combination was a relevant concern (André 
et al. 2014). That same group proceeded to explore whether 
a biomarker in the BOLERO-3 and BOLERO-1 trials could 
better select for patients who would eventually benefit from 
combined therapy. These data suggested that the patients 
who might benefit most from the combination are the ones 
with hyperactive PI3K pathway, either through activating 
mutations in PIK3CA or PTEN loss. However, PIK3CA 
mutational status as a marker for improved PFS in response 
to everolimus reached statistical significance only when 
both studies (BOLERO1 and BOLERO3) were analyzed 
jointly (Andre et al. 2016).
When we compared our trastuzumab-resistant patients 
with TCGA BC cohort, we found that BRAF, EGFR and 
KIT mutations were significantly (P < 0.0020) enriched 
in our patient population. In BRAF, we found one patient 
had a G469E mutation and two others had an I326T muta-
tion. Both are missense mutations. G469E localizes to 
kinase domain and probably leads to hyperactivation of the 
kinase (Davies et  al. 2002), but it has not been described 
in primary breast cancer before (Forbes et  al. 2015). The 
I326T mutation was described in breast cancer cell lines 
Table 5  Mutational landscape of all samples included in the analysis
Sample ID 2 4 8 9 13 20 23 24 27 29 30 31 33 1 5 7 10 11 17 18 28 32 To
ta
l

























PIK3CA 0 0 0 0 1 0 1 1 0 0 0 3 0 3 1 1 0 1 0 1 0 2 15
BRAF 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 1 3
BRCA1 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 1 3
EGFR 0 0 0 0 0 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 3
KIT 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 1 0 0 0 3
NF2 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 1 3
APC 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 2
CTNNB1 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 2
KRAS 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 2
MET 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 2
SMAD4 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 2
SMARCB1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 2
SMO 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 2
WT1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 2
ABL1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1
ATM 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
CSF1R 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
ERBB2 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1
FBXW7 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1
HRAS 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
MAP2K4 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
MSH2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1
NF1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
PTEN 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1
Total: 1 0 0 0 2 3 1 4 1 0 3 13 2 6 4 1 0 4 1 2 0 8
PFS progression-free survival; ER estrogen receptor; + = positive, − = negative; numbers represent the number of mutations in gene, 0 means 
no mutations were found in that gene in that patient (i.e. wild type)
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but its functional effect is yet unknown (Davies et al. 2002; 
Hollestelle et  al. 2007; Sabine et  al. 2014). It is conceiv-
able that activation of B-Raf contributes mechanistically 
to resistance to Her2 blockade by leading to activation of 
the MAPK/ERK signaling pathway independent of engage-
ment of epidermal growth factor receptors.
In KIT, we found two mutations in three patients, both 
localizing to the kinase domain: E839K and V825A. The 
inactivating E839K mutation was described in cutaneous 
mastocytosis and polycythemia vera (Fontalba et al. 2006; 
Longley et al. 1999) and the V825A mutation, also not acti-
vating, had been described in sinonasal lymphoma (Hongyo 
et al. 2000). This leads us to hypothesize that resistance to 
Her2 blockade can develop through intracellular activation 
of multiple different pro-survival signals that do not rely on 
cell surface receptors.
Finally, the R108K and R677H mutations we found in 
EGFR were previously described in glioblastoma (Lee 
et  al. 2006) and glioma (Forbes et  al. 2015). Intracellular 
EGFR signaling shares many of its intermediaries with 
Her2 pathway and hence overactivation of EGFR, making 
Her2 input redundant, is conceivable and lapatinib, which 
inhibits not only HER2/neu but also EGFR, might lead to 
better outcomes in these cases (Clavarezza et al. 2016).
Our findings are consistent with the results of a larger 
study (Nik-Zainal et al. 2016) in which the mutational sig-
nature of ER-positive versus ER-negative tumors was dif-
ferent, even in Her2-positive BC. Hence, we speculate 
that trastuzumab-resistant ER+ Her2-positive BC acquires 
mutations that impair DNA damage repair while trastu-
zumab-resistant  ER− Her2-positive tumors acquire muta-
tions that enhance mitotic signaling.
Limitations
DNA was only available for 22/47 patients enrolled in the 
combined phase I/II trial. This meant there is potential for 
selection bias, although we have no reason to suspect that 
it was the case. It also means that the study might not be 
powered to detect differences between any two groups, 
which might explain why PI3KCA mutations or PTEN 
loss were not prognostic (beta error). Archival material 
was analyzed, and fresh pre- or on-study biopsies were 
not available. Furthermore, samples were not microdis-
sected before DNA extraction. The chip-based  OncoscanTM 
method has its limitations in terms of sensitivity and speci-
ficity (Villegas-Ruiz et al. 2016) and next-generation deep 
genome sequencing is the de facto gold-standard for detect-
ing genomic mutations.
Conclusion
In conclusion, PI3KCA mutation or PTEN loss was not 
prognostic for response to the combination of everolimus 
and trastuzumab in our cohort. Our data shows that muta-
tional burden in heavily treated trastuzumab-resistant Her2-
positive metastatic breast cancer is highly variable and not 
directly correlated with outcome. Activation of the MAPK/
ERK pathway through mutations in EGFR, BRAF or KIT 
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Fig. 1  a Progression-free survival (PFS) does not correlate with total 
number of mutations per patient. Continuous line represents the lin-
ear regression. Dotted line is the 95% confidence interval. P = 0.4429. 
b PFS does not differ according to PIK3CA status (wild type versus 
mutated). P = 0.5335. c PFS does not differ according to PI3K path-
way activation status, defined as PIK3CA mutation and/or PTEN loss. 
P = 0.3232




Tumor biopsies from primary and metastatic sites were 
collected and formalin-fixed/paraffin-embedded before ini-
tiation of everolimus as described (Morrow et  al. 2011b). 
DNA from 36/47 samples was available for us to ana-
lyze. Material was processed for Affymetrix OncoScan™ 
FFPE Express 2.0 Services assay. After exclusion of sam-
ples derived from metastatic sites, we submitted samples 
to quality control based on the amount of DNA (>75  ng 
per ample) and median-absolute pairwise difference 
(MAPD <0.60). Nine ovarian tissue controls were used for 
adequate quality control. After QC, 22 samples and all of 9 
controls were retained for analysis.
Clinical data
Progression-free survival, estrogen receptor status and 
PTEN presence or loss data were collected as part of the 
original study protocol as published (Morrow et al. 2011b). 
PTEN expression levels were based on IHC staining and 
were available for 18/22 patients. All data made available 
for our analysis was de-identified.
Bioinformatics
For each SNP detected by a specific probe in the OncoS-
can™ assay, a somatic mutation score was calculated 
(scorei = abs(xi −휇controls)∕휎controls × sqrt(MAPD i), 
where xi is the contrast of sample i. All calls detected with 
a somatic mutation score >5.0 were considered true posi-
tives. Finally, synonymous SNV were excluded from the 
final analysis.
Data analysis
Using the method described above, 41 somatic mutations 
in 26 genes were identified. We queried TCGA data from 
the Breast Invasive Carcinoma project (Ciriello et al. 2015) 
using cbioportal.org. We queried only mutations and not 
CNA or mRNA expression levels. Furthermore, we queried 
only the genes that were found to be mutated in our cohort. 
We then compared our cohort with the whole breast inva-
sive carcinoma TCGA dataset (n = 1105) or with Her2-pos-
itive breast tumors only (n = 120). We also directly com-
pared the Her2-positive subgroup (n = 120) with TCGA 
Her2-negative BC (n = 985). To analyze differences in gene 
status (mutated versus wild type) in these cohorts, Fisher’s 
exact test was used and P value was defined as significant 
if P < 0.0020 (0.05 divided by 26—Bonferroni correction 
for multiple comparisons, being 26 the number of genes 
included).
We used a log-rank (Mantel–Cox) test to compare sur-
vival curves and statistical significance was defined as 
P < 0.05 for this analysis. All data analysis was done using 
GraphPad Prism (version 6.01 for Windows, GraphPad 
Software, La Jolla California USA, http://www.graphpad.
com).
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